This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Layton Mills and Margaret Curtis agreed to acquire 52% stake in CannPal Animal Therapeutics Limited from AusCann Group Holdings Ltd for AUD1. CI
AusCann Group Holdings Ltd completed the acquisition of CannPal Animal Therapeutics Limited from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others. CI
Cannpal Animal Therapeutics : Narrows Fiscal H1 Loss on Higher Revenue MT
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2020 CI
AusCann : CannPal Managing Director to Lead Merged Company Formed With AusCann; CannPal Rises 11% MT
AusCann Group Holdings Ltd entered into a scheme implementation deed to acquire CannPal Animal Therapeutics Limited from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others for AUD 16.9 million. CI
CannPal Animal Therapeutics Limited Announces Resignation of Max Johnston as Non-Executive Director CI
CannPal Animal Therapeutics Limited Announces Completion of its Safety and Efficacy Study for DermaCann CI
CannPal Animal Therapeutics Limited Announces FDA Establishes Investigational New Animal Drug file for CPAT-01 CI
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2019 CI
CannPal Animal Therapeutics Limited Enters into Exclusive Licensing Agreement with Commonwealth Scientific and Industrial Research Organisation CI
49,365,405 Ordinary Shares of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019. CI
2,000,000 Options of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019. CI
625,000 Class A Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019. CI
1,500,000 Options of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019. CI
7,250,000 Options of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019. CI
625,000 Class B Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019. CI
625,000 Class C Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019. CI
625,000 Class D Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019. CI
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2019 CI
CannPal Animal Therapeutics Limited Commences Phase 2 Pilot Study for Cannabis-Derived Osteoarthritis Drug for Dogs CI
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2018 CI
CannPal Animal Therapeutics Limited Receives Key Ethics Approvals for CPAT-01 Phase 2A Study and Dermacann Skin Study CI
Cannpal Animal Therapeutics Limited Completes Phase 1B Cannabinoid Study in Dogs CI
Cannpal Animal Therapeutics Limited Receives US FDA Sponsor Fee Waiver for Lead Drug Candidate CPAT-01 CI
Chart CannPal Animal Therapeutics Limited
More charts
CannPal Animal Therapeutics Limited is an Australia-based pet pharmaceutical company. The Company is focused on research, developing and commercializing therapeutics for the companion animal health industry, using the compounds derived from the cannabis plants. It is focused on cats and dogs. Its lead drug candidate is CPAT-01, which targets osteosarcoma pain in dogs. It is also engaged in investigating and researching the ability to use cannabidiol derived from the hemp plant for developing a nutraceutical range of products for use in companion animals, including dogs, cats, birds, horses and other domestic animals, without a prescription. It is also developing pharmaceutical therapeutics for chronic pain and appetite stimulation. It is developing nutraceutical products for skin conditions, joint health and digestive health.
More about the company
  1. Stock Market
  2. Equities
  3. CP1 Stock
  4. News CannPal Animal Therapeutics Limited
  5. Cannpal Animal Therapeutics : Narrows Fiscal H1 Loss on Higher Revenue
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW